Wissenschaft & Forschung

Seine engsten wissenschaftlichen Mitarbeiter sind Dr. Martina Sanlorenzo, Dr. Marin Vujic, Dr. Christian Posch und Prof. Klemens Rappersberger. Dazu kommen viele ausgezeichnete Kollegen aus Italien, Österreich und den USA und hervorragende junge Studenten und Diplomanden die allesamt den wissenschaftlichen Drang verspüren und die eine oder andere wissenschaftliche Frage bereits beantworten konnten.

Derzeitige wissenschaftlichen Interessen von Dr. Vujic betreffen vor Allem entzündliche Hauterkrankungen wie die Psorasis und den oralen Lichen ruber planus und den schwarzen Hautkrebs, das Melanom.

Unten finden Sie eine Auflistung von laufenden Forschungsprojekten und bereits publizierten Arbeiten. Aktuelle Publikationen sowie weitere Meßgrößen des wissenschaftlichen Outputes finden sie bitte hier.

Falls sie nähere Fragen zur Forschung und Wissenschaft haben bitte kontaktieren Sie uns unter Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.

Auswahl an wissenschaftlichen Publikationen, laufenden Studien, Vorträgen und Forschungsgeldern:

Priv. Doz. Dr. Igor Vujic – Preise/Grants/Forschungsgelder

(Stand 03/2018)

 LEO Foundation grant, Principal Investigator, DKK 265.000; Project: “Serum transcriptomics in melanoma patients”, Oct 2016-current

Future Leaders in Dermatology, Scholarship, Madrid, Spain, 2016

Imrich Sarkany Memorial-Scholarship, European Academy of Dermatology and Venereology, Copenhagen, DENMARK, 2015

Austrian Dermatology Prize – “UNILEVER Preis”, Vienna, Austria, 2015

Priv. Doz. Dr. Igor Vujic – Auswahl an Vorlesungen, Vorträgen und Poster

(Stand 03/2018)

‘Lehrveranstatung Diagnose und Therapie komplizierter dermatologischer Krankheitsbilder’ Freifach, LV-Nr. 722005, MUW, 2017SS; Vienna, Austria

‘Block 18 2017SS (Studium der Human Medizin) und Block Z1 2017WS (Studium der Zahnmedizin)’ Externer Vortragender; Vienna, Austria

‘Erkrankungen der Mundschleimhaut und Gesichtshaut von Apthen bis zum Zoster’ Fortbildung des Zahnärztlichen Interessenverbandes; 24 January 2018; Vienna, Austria (invited speaker)

‘Melanom - aktueller Stand der Immuntherapie’ 17. Onkologische Wintergespräche; 12-13 January 2018; Vienna, Austria (invited speaker)

‘Melanom – skin cancer’ Best of Dermatology; 20-21 October 2017; Vienna, Austria (invited speaker)

‘Apremilast in der Psoriasis - Real-World Daten für die Praxis’ 5. Wiener Dermatologie Tag; 7 October 2017; Vienna, Austria (invited speaker)

‘Schnitzler syndrome’; 26th EADV Congress; Geneva, 23-17 September 2017 (invited speaker)

‘Hyperactive NRAS downstream signaling induces specific transcriptome changes –esiRNA based identification of new therapeutic targets in NRAS mutant melanoma identifies the noncoding RNA 7SL as a major proliferation enhancer’ Austrian Society of Dermatology and Venerology Meeting; 25-28 Nov. 2016;Vienna, Austria (oral presentation)

‘Hyperactive NRAS downstream signaling induces specific transcriptome changes –esiRNA based identification of new therapeutic targets in NRAS mutant melanoma identifies the noncoding RNA 7SL as a major proliferation enhancer’ Future leaders of Dermatology Meeting; 10-12 Nov. 2016; Madrid, Spain (oral presentation)

‘Fluorescence-Advanced-Videodermatoscopy (FAV): a new method for in-vivo skin evaluation’ Austrian Society of Dermatology and Venerology Meeting; 25-28 Nov. 2016; Vienna, Austria (oral presentation)

‘Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells’ Austrian Society of Dermatology and Venerology Meeting; 4 – 6. December 2016; Vienna, Austria (oral presentation)

‘Pitfalls in the diagnosis of atopic dermatitis’, 25th EADV Congress; 28.Sep – 2.Oct. 2016; Vienna, Austria, (invited speaker)

‘Schnitzler syndrome‘; 24th EADV Congress; 9-12 October 2015; Copenhagen, Denmark (invited speaker)

‘Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer’, Austrian Society of Dermatology and Venerology Meeting; 24-26 November 2014, Vienna, Austria (oral presentation)

‘Anti-PD1 treatment: cutaneous adverse events and correlation with disease progression’. Austrian Society of Dermatology and Venerology Meeting; 21-23 November 2014; Vienna, Austria (poster)

‘Novel long-non-coding RNA in melanoma: MIRAT a biomarker of MEK inhibitor response’. 2015 Keystone Symposia Conference- Long Noncoding RNAs: From Evolution to Function; 15-20 March 2015; Keystone, Colorado, USA (poster)

‘Pembrolizumab treatment: Cutaneous adverse events and correlation with disease progression’. 2015 SID Annual Meeting; 6-9 May 2015; Atlanta, USA (poster)

Priv. Doz. Dr. Igor Vujic – Aktuelle Studien und abgeschlossene Diplomarbeiten und SSM3 Projekte (MUW)

(Stand 03/2018)

‘Ciclosporin A in oral lichen planus – a prospective cohort study’ Diplomarbeit; cand. med. Christina Ellersdorfer

‘Lingua geographica in psoriasis patients’ Diplomarbeit; cand. med. Sofia Grabovac

‘Ustekinumab, Ixekizumab and brodalumab in real world psoriasis patients’ SSM3 Projekt (Med. Uni. Wien) und darausfolgende Diplomarbeit; cand. med. Elina Gugenheimer

‘LncRna als Biomarker im Plasma von PatientInnen mit malignem Melanom - eine Pilotstudie’. Dr. med. Theresa Böhm, 2017

‘Patterns of metastatic spread in sentinel lymph node negative melanomas’. Dr. med. Anna Stöberl, 2016

Priv. Doz. Dr. Igor Vujic – Laufende Studien mit Externen Institutionen

(Stand 07/2020)

‘Which lncRNA in NRAS mutant melanoma are important for cell survival?’ Univeristy of California San Fransico, Ortiz lab.

‘Tumor infiltrating lymphocytes and peptide treatment’. IMBA Wien, Dr. Josef Penninger.

Project IPSZ Biobank IMBA – Rudolfstiftung. IMBA Wien, Dr. Josef Penninger, Dr. Chukwuma Allison Agu

Role of plasmocytoid dendritic cells in melanoma tumors. Comprehensive Cancer Center Vienna. Prof. Maria Sibilia, Dr. Martina Sanlorenzo.

Priv. Doz. Dr. Igor Vujic – Publikationsliste

(Stand 27.03.2018)

Auswahl an publizierten Originalarbeiten in Journalen mit „peer – review System“

(* contributed equally)

1: Strobl K, Klufa J, Jin R, Artner-Gent L, Krauß D, Novoszel P, Strobl J, Stary
G, Vujic I, Griss J, Holcmann M, Farlik M, Homey B, Sibilia M, Bauer T. JAK-
STAT1 as therapeutic target for EGFR deficiency-associated inflammation and
scarring alopecia. EMBO Mol Med. 2024 Nov 9. doi: 10.1038/s44321-024-00166-3.
Epub ahead of print. PMID: 39521937.

2: Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E,
Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen
S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, Daud A, Rappersberger K, Kohwi-
Shigematsu T, Coppé JP, Ortiz-Urda S. The therapeutically actionable long non-
coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven
melanoma. Mol Cancer. 2024 Feb 22;23(1):40. doi: 10.1186/s12943-024-01955-7.
PMID: 38383439; PMCID: PMC10882889.

3: Graier T, Salmhofer W, Jonak C, Weger W, Zikeli C, Gruber B, Sator P,
Prillinger K, Mlynek A, Schütz-Bergmayr M, Richter L, Ratzinger G, Sassmann C,
Painsi C, Häring N, Wippel-Slupetzky K, Skvara H, Trattner H, Inzinger M,
Bangert C, Ellersdorfer C, Falkensteiner K, Sadoghi B, Gruber-Wackernagel A,
Hofer A, Legat F, Lange-Asschenfeldt B, Schmuth M, Vujic I, Hötzenecker W,
Saxinger W, Müllegger R, Quehenberger F, Wolf P. [Entwicklung der
Patientencharakteristika und der Wirksamkeit der Biologika-Therapie bei
Patienten des Österreichischen Psoriasis-Registers von 2004 bis 2022]. J Dtsch
Dermatol Ges. 2023 Dec;21(12):1513-1523. German. doi: 10.1111/ddg.15213_g. PMID:
38082521.

4: Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E,
Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen
S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, Daud A, Rappersberger K, Kohwi-
Shigematsu T, Coppé JP, Ortiz-Urda S. The therapeutically actionable long non-
coding RNA '<i>T-RECS</i>' is essential to cancer cells' survival in NRAS/MAPK-
driven melanoma. Res Sq [Preprint]. 2023 Dec 1:rs.3.rs-1297358. doi:
10.21203/rs.3.rs-1297358/v3. Update in: Mol Cancer. 2024 Feb 22;23(1):40. doi:
10.1186/s12943-024-01955-7. PMID: 38077055; PMCID: PMC10705697.

5: Graier T, Salmhofer W, Jonak C, Weger W, Zikeli C, Gruber B, Sator P,
Prillinger K, Mlynek A, Schütz-Bergmayr M, Richter L, Ratzinger G, Sassmann C,
Painsi C, Häring N, Wippel-Slupetzky K, Skvara H, Trattner H, Inzinger M,
Bangert C, Ellersdorfer C, Falkensteiner K, Sadoghi B, Gruber-Wackernagel A,
Hofer A, Legat F, Lange-Asschenfeldt B, Schmuth M, Vujic I, Hötzenecker W,
Saxinger W, Müllegger R, Quehenberger F, Wolf P. Evolution of characteristics
and biologic treatment effectiveness in patients of the Austrian psoriasis
registry from 2004-2022. J Dtsch Dermatol Ges. 2023 Dec;21(12):1513-1523. doi:
10.1111/ddg.15213. Epub 2023 Oct 31. PMID: 37907427.

6: Antiga E, Bech R, Maglie R, Genovese G, Borradori L, Bockle B, Caproni M,
Caux F, Chandran NS, Corrà A, D'Amore F, Daneshpazhooh M, De D, Didona D,
Dmochowski M, Drenovska K, Ehrchen J, Feliciani C, Goebeler M, Groves R, Günther
C, Handa S, Hofmann SC, Horvath B, Ioannidis D, Jedlickova H, Kowalewski C,
Kridin K, Joly P, Lim YL, Marinovic B, Maverakis E, Meijer J, Patsatsi A,
Pincelli C, Prost C, Setterfield J, Sprecher E, Skiljevic D, Tasanen K, Uzun S,
Van Beek N, Vassileva S, Vorobyev A, Vujic I, Wang G, Wang M, Wozniak K, Yayli
S, Zambruno G, Hashimoto T, Schmidt E, Mascarò JM Jr, Marzano AV. Corrigendum:
S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic
autoimmune multiorgan syndrome initiated by the European Academy of Dermatology
and Venereology (EADV). J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2378-2379.
doi: 10.1111/jdv.19489. Epub 2023 Sep 13. Erratum for: J Eur Acad Dermatol
Venereol. 2023 Jun;37(6):1118-1134. doi: 10.1111/jdv.18931. PMID: 37702229.

7: Antiga E, Bech R, Maglie R, Genovese G, Borradori L, Bockle B, Caproni M,
Caux F, Chandran NS, Corrà A, D'Amore F, Daneshpazhooh M, De D, Didona D,
Dmochowski M, Drenovska K, Ehrchen J, Feliciani C, Goebeler M, Groves R, Günther
C, Handa S, Hofmann SC, Horvath B, Ioannidis D, Jedlickova H, Kowalewski C,
Kridin K, Joly P, Lim YL, Marinovic B, Maverakis E, Meijer J, Patsatsi A,
Pincelli C, Prost C, Setterfield J, Sprecher E, Skiljevic D, Tasanen K, Uzun S,
Van Beek N, Vassileva S, Vorobyev A, Vujic I, Wang G, Wang M, Wozniak K, Yayli
S, Zambruno G, Hashimoto T, Schmidt E, Mascarò JM Jr, Marzano AV. S2k guidelines
on the management of paraneoplastic pemphigus/paraneoplastic autoimmune
multiorgan syndrome initiated by the European Academy of Dermatology and
Venereology (EADV). J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1118-1134. doi:
10.1111/jdv.18931. Epub 2023 Mar 25. Erratum in: J Eur Acad Dermatol Venereol.
2023 Nov;37(11):2378-2379. doi: 10.1111/jdv.19489. PMID: 36965110; PMCID:
PMC10806824.

8: Jonak C, Göttfried I, Perl-Convalexius S, Gruber B, Schütz-Bergmayr M, Vujic
I, Weger W, Schicher N, Semlin L, Hemetsberger M, Cordey M, Sator P.
Characteristics and outcomes of patients with psoriasis treated with apremilast
in the real-world in Austria - results the APPRECIATE study. Ther Adv Chronic
Dis. 2023 Feb 7;14:20406223231152785. doi: 10.1177/20406223231152785. PMID:
36777399; PMCID: PMC9909071.

9: Rotolo R, Leuci V, Donini C, Galvagno F, Massa A, De Santis MC, Peirone S,
Medico G, Sanlorenzo M, Vujic I, Gammaitoni L, Basiricò M, Righi L, Riganti C,
Salaroglio IC, Napoli F, Tabbò F, Mariniello A, Vigna E, Modica C, D'Ambrosio L,
Grignani G, Taulli R, Hirsch E, Cereda M, Aglietta M, Scagliotti GV, Novello S,
Bironzo P, Sangiolo D. Novel Lymphocyte-Independent Antitumor Activity by PD-1
Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells. Clin Cancer
Res. 2023 Feb 1;29(3):621-634. doi: 10.1158/1078-0432.CCR-22-0761. PMID:
36165915; PMCID: PMC9890136.

10: Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Daud A, Algazi A, Rappersberger K,
Ortiz-Urda S. Melanoma risk during immunomodulating treatment. Melanoma Res.
2022 Dec 1;32(6):411-418. doi: 10.1097/CMR.0000000000000838. Epub 2022 Aug 22.
PMID: 35993892.

11: Weltler P, Rappersberger K, Filzmoser P, Vujic I. The impact of the COVID-19
pandemic on melanoma diagnoses. JEADV Clin Pract. 2022 Jun;1(2):122-125. doi:
10.1002/jvc2.15. Epub 2022 Mar 13. PMID: 37829553; PMCID: PMC9088572.

12: Perschy L, Anzengruber F, Rappersberger K, Itzlinger-Monshi B, Aichelburg
MC, Graf V, Hafner J, Vujic I. Apremilast bei oralem Lichen planus - eine
multizentrische, retrospektive Studie. J Dtsch Dermatol Ges. 2022
Mar;20(3):343-348. doi: 10.1111/ddg.14696_g. PMID: 35304956.

13: Perschy L, Anzengruber F, Rappersberger K, Itzlinger-Monshi B, Aichelburg
MC, Graf V, Hafner J, Vujic I. Apremilast in oral lichen planus - a
multicentric, retrospective study. J Dtsch Dermatol Ges. 2022 Mar;20(3):343-346.
doi: 10.1111/ddg.14696. Epub 2022 Feb 18. PMID: 35181989.

14: Monshi B, Ellersdorfer C, Edelmayer M, Dvorak G, Ganger C, Ulm C,
Rappersberger K, Vujic I. Topical Cyclosporine in Oral Lichen Planus-A Series of
21 Open-Label, Biphasic, Single-Patient Observations. J Clin Med. 2021 Nov
22;10(22):5454. doi: 10.3390/jcm10225454. PMID: 34830736; PMCID: PMC8622196.

15: Graier T, Weger W, Sator PG, Salmhofer W, Gruber B, Jonak C, Kölli C,
Schütz-Bergmayr M, Vujic I, Ratzinger G, Häring N, Painsi C, Prillinger K,
Mlynek A, Skvara H, Trattner H, Tanew A, Lichem R, Ellersdorfer C, Legat F,
Gruber-Wackernagel A, Hofer A, Schmiedberger E, Hoetzenecker W, Müllegger R,
Saxinger W, Quehenberger F, Wolf P. Effectiveness and clinical predictors of
drug survival in psoriasis patients receiving apremilast: A registry analysis.
JAAD Int. 2020 Dec 26;2:62-75. doi: 10.1016/j.jdin.2020.10.012. Erratum in: JAAD
Int. 2021 Mar 16;3:53. doi: 10.1016/j.jdin.2021.02.005. PMID: 34409355; PMCID:
PMC8362309.

16: Monshi B, Grabovac S, Gulz L, Ellersdorfer C, Vujic M, Richter L,
Kivaranovic D, Rappersberger K, Vujic I. Psoriasis ist mit Lingua plicata jedoch
nicht mit Lingua geographica assoziiert: eine prospektive Fall-Kontroll-Studie.
J Dtsch Dermatol Ges. 2021 Aug;19(8):1170-1177. German. doi:
10.1111/ddg.14451_g. PMID: 34390146.

17: Monshi B, Grabovac S, Gulz L, Ellersdorfer C, Vujic M, Richter L,
Kivaranovic D, Rappersberger K, Vujic I. Psoriasis is associated with fissured
tongue but not geographic tongue: a prospective, cross-sectional, case-control
study. J Dtsch Dermatol Ges. 2021 Aug;19(8):1170-1176. doi: 10.1111/ddg.14451.
Epub 2021 Jun 10. PMID: 34114338.

18: Wiala A, Vujic I, Richter L, Rappersberger K, Posch C. Dermatomyositis
erfordert eine kombinierte Langzeittherapie mit Immunsuppressiva und
intravenösen Immunglobulinen. J Dtsch Dermatol Ges. 2021 Mar;19(3):456-459.
German. doi: 10.1111/ddg.14365_g. PMID: 33709576.

19: Wiala A, Vujic I, Richter L, Rappersberger K, Posch C. Dermatomyositis
requires long-term treatment with combined immunosuppressive and immunoglobulin
therapy. J Dtsch Dermatol Ges. 2021 Mar;19(3):456-458. doi: 10.1111/ddg.14365.
Epub 2021 Feb 15. PMID: 33586296.

20: Klufa J, Bauer T, Hanson B, Herbold C, Starkl P, Lichtenberger B, Srutkova
D, Schulz D, Vujic I, Mohr T, Rappersberger K, Bodenmiller B, Kozakova H, Knapp
S, Loy A, Sibilia M. Hair eruption initiates and commensal skin microbiota
aggravate adverse events of anti-EGFR therapy. Sci Transl Med. 2019 Dec
11;11(522):eaax2693. doi: 10.1126/scitranslmed.aax2693. PMID: 31826981.

21: Grieb A, Kaderschabek N, Orasche C, Minkov M, Sanlorenzo M, Rappersberger K,
Vujic I. Mycoplasma-pneumoniae-assoziierte Mukositis mit Hautbeteiligung - ein
Fallbericht. J Dtsch Dermatol Ges. 2019 Feb;17(2):184-185. doi:
10.1111/ddg.13714_g. PMID: 30762956.

22: Feichtenschlager V, Weihsengruber F, Richter L, Vujic I, Rappersberger K,
Posch C. Clinical melanoma characteristics and survival-a single-center
retrospective study between 2000 and 2010. Wien Med Wochenschr. 2019
Oct;169(13-14):323-330. English. doi: 10.1007/s10354-018-0678-3. Epub 2019 Jan
16. PMID: 30649651.

23: Grieb A, Kaderschabek N, Orasche C, Minkov M, Sanlorenzo M, Rappersberger K,
Vujic I. Mycoplasma pneumoniae-associated mucositis with cutaneous involvement -
a case report. J Dtsch Dermatol Ges. 2019 Feb;17(2):184-185. doi:
10.1111/ddg.13714. Epub 2018 Dec 3. PMID: 30507029.

24: Vujic I, Gandini S, Stanganelli I, Fierro MT, Rappersberger K, Sibilia M,
Tosti G, Ferrucci PF, Caini S, De Felici MB, Pagliarello C, Quaglino P,
Sanlorenzo M; IMI, the Italian Melanoma Intergroup. A meta-analysis of melanoma
risk in industrial workers. Melanoma Res. 2020 Jun;30(3):286-296. doi:
10.1097/CMR.0000000000000531. PMID: 30371537.

25: Sanlorenzo M, Vujic I, Esteve-Puig R, Lai K, Vujic M, Lin K, Posch C, Dimon
M, Moy A, Zekhtser M, Johnston K, Gho D, Ho W, Gajjala A, Oses Prieto J,
Burlingame A, Daud A, Rappersberger K, Ortiz-Urda S. The lincRNA MIRAT binds to
IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Sci Rep. 2018 Jul
19;8(1):10902. doi: 10.1038/s41598-018-27643-3. PMID: 30026510; PMCID:
PMC6053443.

26: Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, Macagno
M, Leuci V, Rotolo R, Donini C, Basiricò M, Quaglino P, Fierro MT, Giordano S,
Sibilia M, Carnevale-Schianca F, Aglietta M, Sangiolo D. BRAF and MEK Inhibitors
Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-
Independent Synergism with Anti-PD-1 Antibody. Clin Cancer Res. 2018 Jul
15;24(14):3377-3385. doi: 10.1158/1078-0432.CCR-17-1914. Epub 2018 Apr 12. PMID:
29650750.

27: Posch C, Monshi B, Quint T, Vujic I, Lilgenau N, Rappersberger K. The role
of wide local excision for the treatment of severe hidradenitis suppurativa
(Hurley grade III): Retrospective analysis of 74 patients. J Am Acad Dermatol.
2017 Jul;77(1):123-129.e5. doi: 10.1016/j.jaad.2017.01.055. Epub 2017 Apr 1.
PMID: 28377030.

28: Sanlorenzo M, Vujic I, Carnevale-Schianca F, Quaglino P, Gammaitoni L,
Fierro MT, Aglietta M, Sangiolo D. Role of interferon in melanoma: old hopes and
new perspectives. Expert Opin Biol Ther. 2017 Apr;17(4):475-483. doi:
10.1080/14712598.2017.1289169. Epub 2017 Feb 16. Erratum in: Expert Opin Biol
Ther. 2018 Mar;18(3):1. doi: 10.1080/14712598.2018.1433279. PMID: 28274138.

29: Richter L, Vujic I, Sesti A, Monshi B, Sanlorenzo M, Posch C, Rappersberger
K. Etanercept, Adalimumab und Ustekinumab bei Psoriasis: Analyse von 209
Behandlungsreihen in Österreich. J Dtsch Dermatol Ges. 2017 Mar;15(3):309-318.
doi: 10.1111/ddg.13191_g. PMID: 28252852.

30: Richter L, Vujic I, Sesti A, Monshi B, Sanlorenzo M, Posch C, Rappersberger
K. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209
treatment series in Austria. J Dtsch Dermatol Ges. 2017 Mar;15(3):309-317. doi:
10.1111/ddg.13191. Epub 2017 Feb 27. PMID: 28240404.

31: Kwong A, Sanlorenzo M, Rappersberger K, Vujic I. Update on advanced melanoma
treatments: small molecule targeted therapy, immunotherapy, and future
combination therapies. Wien Med Wochenschr. 2019 Oct;169(13-14):314-322.
English. doi: 10.1007/s10354-016-0535-1. Epub 2017 Jan 13. PMID: 28091975.

32: Moreno-Traspas R, Vujic I, Sanlorenzo M, Ortiz-Urda S. New insights in
melanoma biomarkers: long-noncoding RNAs. Melanoma Manag. 2016 Sep;3(3):195-205.
doi: 10.2217/mmt-2016-0008. Epub 2016 Aug 16. PMID: 30190889; PMCID: PMC6094599.

33: Dapavo P, Vujic I, Fierro MT, Quaglino P, Sanlorenzo M. The infliximab
biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad
Dermatol. 2016 Oct;75(4):736-739. doi: 10.1016/j.jaad.2016.04.068. Epub 2016 Jul
26. PMID: 27473452.

34: Posch C, Moslehi H, Sanlorenzo M, Green G, Vujic I, Panzer-Grümayer R,
Rappersberger K, Ortiz-Urda S. Pharmacological inhibitors of c-KIT block mutant
c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.
Oncotarget. 2016 Jul 19;7(29):45916-45925. doi: 10.18632/oncotarget.10001. PMID:
27322141; PMCID: PMC5216770.

35: Posch C, Sanlorenzo M, Vujic I, Oses-Prieto JA, Cholewa BD, Kim ST, Ma J,
Lai K, Zekhtser M, Esteve-Puig R, Green G, Chand S, Burlingame AL, Panzer-
Grümayer R, Rappersberger K, Ortiz-Urda S. Phosphoproteomic Analyses of
NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels
in NRAS(Q61) Mutant Cells. J Invest Dermatol. 2016 Oct;136(10):2041-2048. doi:
10.1016/j.jid.2016.05.098. Epub 2016 May 29. PMID: 27251789; PMCID: PMC6373467.

36: Posch C, Vujic I, Monshi B, Sanlorenzo M, Weihsengruber F, Rappersberger K,
Ortiz-Urda S. Searching for the Chokehold of NRAS Mutant Melanoma. J Invest
Dermatol. 2016 Jul;136(7):1330-1336. doi: 10.1016/j.jid.2016.03.006. Epub 2016
May 7. PMID: 27160069; PMCID: PMC4921268.

37: Monshi B, Vujic M, Kivaranovic D, Sesti A, Oberaigner W, Vujic I, Ortiz-Urda
S, Posch C, Feichtinger H, Hackl M, Rappersberger K. The burden of malignant
melanoma--lessons to be learned from Austria. Eur J Cancer. 2016 Mar;56:45-53.
doi: 10.1016/j.ejca.2015.11.026. Epub 2016 Jan 20. PMID: 26802530.

38: Vujic I, Sanlorenzo M, Esteve-Puig R, Vujic M, Kwong A, Tsumura A, Murphy R,
Moy A, Posch C, Monshi B, Rappersberger K, Ortiz-Urda S. Acyl protein
thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349
have different effects on NRAS mutant melanoma cells. Oncotarget. 2016 Feb
9;7(6):7297-306. doi: 10.18632/oncotarget.6907. PMID: 26771141; PMCID:
PMC4872786.

39: Sanlorenzo M, Vujic I, Ortiz-Urda S. Time-Dependent Measurement of Adverse
Events-Reply. JAMA Dermatol. 2015 Dec 1;151(12):1392-1393. doi:
10.1001/jamadermatol.2015.3578. PMID: 26650664; PMCID: PMC11037295.

40: Stöllberger C, Vujic I, Wollmann E, Freudenthaler J, Finsterer J. Carvajal
syndrome with oligodontia, hypoacusis, recurrent infections, and noncompaction.
Int J Cardiol. 2016 Jan 15;203:825-7. doi: 10.1016/j.ijcard.2015.11.050. Epub
2015 Nov 6. PMID: 26599742.

41: Vigl K, Monshi B, Vujic I, Rappersberger K. Pyoderma gangrenosum-like
necrotizing panniculitis associated with alpha-1 antitrypsin deficiency: a
lethal course. J Dtsch Dermatol Ges. 2015 Nov;13(11):1180-4. doi:
10.1111/ddg.12830. PMID: 26513086.

42: Goldenberg A, Vujic I, Sanlorenzo M, Ortiz-Urda S. Melanoma risk perception
and prevention behavior among African-Americans: the minority melanoma paradox.
Clin Cosmet Investig Dermatol. 2015 Aug 5;8:423-9. doi: 10.2147/CCID.S87645.
PMID: 26346576; PMCID: PMC4531028.

43: Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino
P, Rappersberger K, Ortiz-Urda S. Pembrolizumab Cutaneous Adverse Events and
Their Association With Disease Progression. JAMA Dermatol. 2015
Nov;151(11):1206-1212. doi: 10.1001/jamadermatol.2015.1916. PMID: 26222619;
PMCID: PMC5061067.

44: Sanlorenzo M, Vujic I, Moy A, Quaglino P, Fierro MT, Gammaitoni L,
Carnevale-Schianca F, Aglietta M, Sangiolo D. Synergy of molecular targeted
approaches and immunotherapy in melanoma: preclinical basis and clinical
perspectives. Expert Opin Biol Ther. 2015;15(10):1491-500. doi:
10.1517/14712598.2015.1069272. Epub 2015 Jul 24. PMID: 26206099.

45: Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Correction: Cost-
Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS
One. 2015 Apr 20;10(4):e0126988. doi: 10.1371/journal.pone.0126988. Erratum for:
PLoS One. 2014 Sep 08;9(9):e107255. doi: 10.1371/journal.pone.0107255. PMID:
25893993; PMCID: PMC4404367.

46: Posch C, Latorre A, Crosby MB, Celli A, Latorre A, Vujic I, Sanlorenzo M,
Green GA, Weier J, Zekhtser M, Ma J, Monico G, Char DH, Jusufbegovic D,
Rappersberger K, Somoza Á, Ortiz-Urda S. Detection of GNAQ mutations and
reduction of cell viability in uveal melanoma cells with functionalized gold
nanoparticles. Biomed Microdevices. 2015 Feb;17(1):15. doi:
10.1007/s10544-014-9908-7. PMID: 25653058; PMCID: PMC4586106.

47: Sanlorenzo M, Vujic I, Posch C, Cleaver JE, Quaglino P, Ortiz-Urda S. The
risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes.
JAMA Dermatol. 2015 Apr;151(4):450-2. doi: 10.1001/jamadermatol.2014.4643. PMID:
25517516; PMCID: PMC4476387.

48: Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A,
Murphy R, Rappersberger K, Ortiz-Urda S. Metformin and trametinib have
synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Oncotarget. 2015 Jan 20;6(2):969-78. doi: 10.18632/oncotarget.2824. PMID:
25504439; PMCID: PMC4359268.

49: Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M,
Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S.
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination
therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014
Dec;71(6):1102-1109.e1. doi: 10.1016/j.jaad.2014.09.002. Epub 2014 Oct 16. PMID:
25440439; PMCID: PMC4254519.

50: Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager
V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM. Mutant NRASQ61 shares
signaling similarities across various cancer types--potential implications for
future therapies. Oncotarget. 2014 Sep 15;5(17):7936-44. doi:
10.18632/oncotarget.2326. PMID: 25277205; PMCID: PMC4202171.

51: Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Cost-effectiveness
of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One. 2014 Sep
8;9(9):e107255. doi: 10.1371/journal.pone.0107255. Erratum in: PLoS One. 2015
Apr 20;10(4):e0126988. doi: 10.1371/journal.pone.0126988. PMID: 25198196; PMCID:
PMC4157865.

52: Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, Vujic I,
Johnston K, Gho D, Monico G, McGrath JT, Osella-Abate S, Quaglino P, Cleaver JE,
Ortiz-Urda S. The risk of melanoma in airline pilots and cabin crew: a meta-
analysis. JAMA Dermatol. 2015 Jan;151(1):51-8. doi:
10.1001/jamadermatol.2014.1077. PMID: 25188246; PMCID: PMC4482339.

53: Monshi B, Posch C, Vujic I, Sesti A, Sobotka S, Rappersberger K. Efficacy of
intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11
patients. J Am Acad Dermatol. 2014 Oct;71(4):738-44. doi:
10.1016/j.jaad.2014.05.039. Epub 2014 Jul 9. PMID: 25022849.

54: Latorre A, Posch C, Garcimartín Y, Celli A, Sanlorenzo M, Vujic I, Ma J,
Zekhtser M, Rappersberger K, Ortiz-Urda S, Somoza Á. DNA and aptamer stabilized
gold nanoparticles for targeted delivery of anticancer therapeutics. Nanoscale.
2014 Jul 7;6(13):7436-42. doi: 10.1039/c4nr00019f. PMID: 24882040.

55: Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum
MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. Melanoma
immunotherapy. Cancer Biol Ther. 2014 Jun 1;15(6):665-74. doi:
10.4161/cbt.28555. Epub 2014 Mar 20. PMID: 24651672; PMCID: PMC4049781.

56: Vujic I, Richter L, Bartsch K, Monshi B, Rappersberger K. Pityriasis rubra
pilaris types 1 and 2: different responses to treatment with TNF-alpha
antagonists. Eur J Dermatol. 2013 Nov-Dec;23(6):895-6. doi:
10.1684/ejd.2013.2175. PMID: 24192269.